SCHEMBL15426843

SCHEMBL15426843

Cc1ccc(F)cc1OCc1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 3/20 0.65
FFAR1 O14842 2/20 0.65
L3MBTL1 Q9Y468 3/20 0.58
MAPT P10636 2/20 0.58
MAPK1 P28482 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
MRGPRX4 Q96LA9 2/20 0.52
RXRA P19793 1/20 0.50
RXRB P28702 1/20 0.50
RXRG P48443 1/20 0.50
LMNA P02545 2/20 0.49
STAT3 P40763 2/20 0.49
HTT P42858 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
POLB P06746 1/20 0.49
ALDH1A1 P00352 1/20 0.49
PKM P14618 1/20 0.49
LIPE Q05469 1/20 0.49
KDM1A O60341 3/20 0.47
MEN1 O00255 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19155129 0.89 FFAR4 (0.68) FFAR4FFAR1MAPTMRGPRX4RXRA
SCHEMBL14228414 0.82 MAPT (0.56) FFAR4L3MBTL1MAPTMAPK1TDP1
SCHEMBL4228617 0.81 FFAR1 (0.66) FFAR4FFAR1L3MBTL1MAPTMAPK1
SCHEMBL12301124 0.81 MRGPRX4 (0.58) L3MBTL1MAPTMAPK1TDP1MRGPRX4
SCHEMBL21667956 0.81 FFAR1 (0.58) FFAR4FFAR1L3MBTL1MAPTMAPK1
SCHEMBL30002764 0.81 FFAR1 (0.66) FFAR4FFAR1L3MBTL1MAPTMAPK1
SCHEMBL25081934 0.81 MAPT (0.64) FFAR4L3MBTL1MAPTMAPK1TDP1
SCHEMBL265584 0.81 MAPK1 (0.70) FFAR4L3MBTL1MAPTMAPK1TDP1
SCHEMBL29874217 0.81 MAPK1 (0.70) FFAR4L3MBTL1MAPTMAPK1TDP1
SCHEMBL2912541 0.81 MAPT (0.55) FFAR4FFAR1L3MBTL1MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11664093-B2 Extrapolative prediction of enantioselectivity enabled by computer-driven workflow, new molecular representations and machine learning THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2023-05-30 US disclosed
US-8999982-B2 Pharmaceutically active compounds as Axl inhibitors LEAD DISCOVERY CENTER GMBH (DE) 2015-04-07 US disclosed
EP-2609091-B1 PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS LEAD DISCOVERY CENTER GMBH (DE) 2014-11-26 EP disclosed
US-20140018365-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCCHAFTEN E.V. (DE) 2014-01-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140018365-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS AXL, FLT3, ERBB3 FFAR4 1231/4885FFAR1 661/4885L3MBTL1 2878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.